MARINUS PHARMACEUTICALS, INC.
marinuspharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 12, 2024. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2025.
10-Q for Q3 FY2024, filed Nov 12, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells an oral medicine for seizures linked to a rare genetic disorder, and develops ganaxolone for other rare epilepsies and prolonged seizures.
10-K for FY2023, filed Mar 5, 2024We are a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure…View ↗
We are also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for…View ↗
ZTALMY is an oral suspension given three times per day that we have developed for the treatment of CDD-associated seizures. ZTALMY was…View ↗
How Did They Make Money?
Marinus sells ZTALMY through specialty pharmacy orders and delivers it to Orsini; Orsini's payment is due after shipment.
10-K for FY2023, filed Mar 5, 2024Our first FDA approved product, ZTALMY, became available for commercial sale and shipment to patients in the third quarter of 2022. We have…View ↗
Our first FDA approved product, ZTALMY, became available for commercial sale and shipment to patients in the third quarter of 2022. We have…View ↗
Net trade receivables related to ZTALMY sales, which are recorded in Accounts receivable, net on the consolidated balance sheets, were…View ↗
$31M
-
10-K for FY2023, filed Mar 5, 2024
$31M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2023, filed Mar 5, 2024 |
100% |
Product revenue, net, FY2023
$19.6M Sources
|
Sold outright |
|
Collaboration revenue
|
0.3% |
Collaboration revenue, FY2023
$54K Sources
|
Who Were Their Customers?
In the U.S., ZTALMY is dispensed directly to patients by a specialty pharmacy; a specialty distributor serves institutional inpatient pharmacies, government customers and Kaiser Permanente.
10-K for FY2023, filed Mar 5, 2024
Did Revenues Turn Into Profits?
No. It lost $141.4M in FY2023.
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 12, 2024
−$24.2MView ↗
- ▼ −27% (Loss)
- vs −$33M in Q3 FY2023
10-Q for Q3 FY2024, filed Nov 12, 2024
Open tableView ↗
-
Feb 11, 2025
Immedica completed its acquisition of Marinus
Marinus became an indirect wholly owned subsidiary, and its stock ceased trading on Nasdaq.
Sources
8-K, filed Feb 11, 2025
On February 11, 2025 (the “Closing Date”), pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company, with…View ↗
-
Dec 30, 2024
Marinus terminated its European commercialization and supply agreements with Orion
Sources
8-K, filed Dec 30, 2024
On December 23, 2024 (the “Termination Effective Date”), Marinus Pharmaceuticals, Inc. (the “Company”) and Orion Corporation (“Orion”)…View ↗
-
Nov 12, 2024
Narrowed 2024 ZTALMY revenue guidance to $33 to $34 million
The range changed from $33 to $35 million to $33 to $34 million.
Sources
8-K, filed Nov 12, 2024
Narrowing full year 2024 net product revenue guidance to $33 to $34 million from a range of $33 to $35 million.View ↗
From candidate to sales
The earlier report described ganaxolone as a clinical-stage candidate; the latest describes ZTALMY as an approved medicine available for sale, while ganaxolone remains in development for other seizure disorders.
10-K for FY2020, filed Mar 9, 2021 10-K for FY2023, filed Mar 5, 2024We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients…View ↗
Who Did They Compete With?
Competes with Bio-Pharm Solutions, Novartis Pharmaceuticals, Jazz Pharmaceuticals, UCB, Noema Pharma, Ovid, Assertio Holdings, Takeda Pharmaceutical, and SK Life Science
10-K for FY2023, filed Mar 5, 2024SE patients generally are treated with benzodiazepines as first-line treatment. When benzodiazepines are not effective, patients are…View ↗
Loading...
